Pneumonectomy after induction chemoradiotherapy for locally advanced non-small cell lung cancer: should curative intent pulmonary resection be avoided?


Journal

Surgery today
ISSN: 1436-2813
Titre abrégé: Surg Today
Pays: Japan
ID NLM: 9204360

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 19 06 2017
accepted: 27 11 2017
pubmed: 6 1 2019
medline: 4 4 2019
entrez: 6 1 2019
Statut: ppublish

Résumé

We conducted a retrospective analysis to assess the practicality of pneumonectomy, especially after concurrent induction chemoradiotherapy (i-CRT), for locally advanced non-small cell lung cancer (LA-NSCLC). The operative risks vs. the survival benefit of this procedure for such patients is a subject of controversy. The subjects of this retrospective study were 71 consecutive LA-NSCLC patients with cStage IIIA-C NSCLC, who underwent i-CRT followed by curative intent pulmonary resection between February, 2001 and March, 2013. Thirty-two patients underwent pneumonectomy (group P) and 39 patients underwent lobectomy (group L). In group P, 17 (54.8%) patients underwent right pneumonectomy. There was no 30-day postoperative mortality in either group and no significant difference in 90-day postoperative mortality between the groups (3.1% vs. 2.6% in groups P and L, respectively). The 5-year overall survival (OS) rate was 58.7% (95% CI: 41.5-75.9%) in group P and 57.3% (95% CI 41.2-73.4%) in group L, without a significant difference between the groups. Our findings suggest that i-CRT followed by pneumonectomy is feasible, with a similar survival benefit to lobectomy. Thus, pneumonectomy after i-CRT should not be avoided as it is a potentially curative intent strategy for carefully selected patients.

Identifiants

pubmed: 30610361
doi: 10.1007/s00595-018-1751-7
pii: 10.1007/s00595-018-1751-7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

197-205

Références

J Thorac Cardiovasc Surg. 2000 Apr;119(4 Pt 1):814-9
pubmed: 10733774
Ann Thorac Surg. 2004 Apr;77(4):1152-6; discussion 1156
pubmed: 15063224
Clin Cancer Res. 2004 Jul 1;10(13):4369-73
pubmed: 15240524
Ann Thorac Surg. 2005 Apr;79(4):1147-52; discussion 1147-52
pubmed: 15797042
J Thorac Cardiovasc Surg. 2005 Aug;130(2):416-25
pubmed: 16077407
Ann Thorac Surg. 2005 Dec;80(6):2046-50
pubmed: 16305842
Eur J Cardiothorac Surg. 2006 Mar;29(3):276-80
pubmed: 16434204
Ann Thorac Surg. 2006 Jul;82(1):227-31
pubmed: 16798219
Eur J Cardiothorac Surg. 2007 Jan;31(1):95-102
pubmed: 17126556
Cancer. 2008 Mar 1;112(5):1106-13
pubmed: 18286507
J Thorac Oncol. 2008 Jun;3(6):604-8
pubmed: 18520798
J Thorac Cardiovasc Surg. 2008 Nov;136(5):1349-56
pubmed: 19026827
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Lancet Oncol. 2009 Aug;10(8):785-93
pubmed: 19604722
J Thorac Cardiovasc Surg. 2009 Aug;138(2):289-94
pubmed: 19619768
Lancet. 2009 Aug 1;374(9687):379-86
pubmed: 19632716
Ann Thorac Surg. 2009 Oct;88(4):1079-85
pubmed: 19766784
J Thorac Oncol. 2010 Apr;5(4):517-20
pubmed: 20104190
J Thorac Cardiovasc Surg. 2010 Jun;139(6):1424-30
pubmed: 20416887
Thorax. 2010 Oct;65 Suppl 3:iii1-27
pubmed: 20940263
J Thorac Oncol. 2011 Dec;6(12):2069-75
pubmed: 22052226
J Thorac Oncol. 2013 May;8(5):637-43
pubmed: 23584296
Chest. 2013 May;143(5 Suppl):e314S-e340S
pubmed: 23649445
Ann Oncol. 2013 Oct;24 Suppl 6:vi89-98
pubmed: 23860613
Ann Thorac Surg. 2013 Nov;96(5):1783-9
pubmed: 23998404
Lancet. 2015 Sep 12;386(9998):1049-56
pubmed: 26275735
J Clin Oncol. 2015 Dec 10;33(35):4194-201
pubmed: 26527789
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
Ann Thorac Surg. 1995 Sep;60(3):615-22; discussion 622-3
pubmed: 7677489

Auteurs

Masafumi Yamaguchi (M)

Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka City, 811-1395, Japan. masafumiyamaguchi@yahoo.co.jp.

Shinichiro Shimamatsu (S)

Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka City, 811-1395, Japan.

Makoto Edagawa (M)

Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka City, 811-1395, Japan.

Fumihiko Hirai (F)

Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka City, 811-1395, Japan.

Ryo Toyozawa (R)

Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka City, 811-1395, Japan.

Kaname Nosaki (K)

Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka City, 811-1395, Japan.

Takashi Seto (T)

Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka City, 811-1395, Japan.

Mitsuhiro Takenoyama (M)

Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka City, 811-1395, Japan.

Yukito Ichinose (Y)

Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka City, 811-1395, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH